Review Article

BioDrugs

, Volume 15, Issue 4, pp 251-259

First online:

Tumour Necrosis Factor-α Blockers in Rheumatoid Arthritis

Review of the Clinical Experience
  • Corinne Richard-MiceliAffiliated withClinique de Rhumatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université René DescartesCentre d’Etude du Polymorphisme Humain, Hôpital Saint-Louis
  • , Maxime DougadosAffiliated withClinique de Rhumatologie, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Université René Descartes Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Tumour necrosis factor (TNF)-α has been found to play a central role in the pathogenesis of rheumatoid arthritis, leading to development of novel drug therapies that neutralise the deleterious effects of this cytokine. This new concept of immunobiological treatment of rheumatoid arthritis has yielded successful results. Although the 2 currently available TNFα blockers, infliximab and etanercept, differ in structure, mechanism of action and pharmacokinetics, they have provided similar benefits both in clinical improvement and in slowing and even arresting the progression of radiographic damage. This therapeutic response seems to be unequalled by ‘conventional’ treatments in rheumatoid arthritis, and is incontestably a turning point in the therapeutic management of this disease.